Open AccessBTK Inhibitor Offers Benefits of Ibrutinib Without Cardio Side Effects
Author(s) -
Chuck Holt
Publication year - 2018
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000534129.72528.24
Subject(s) - ibrutinib , bruton's tyrosine kinase , pharmacology , medicine , tyrosine kinase , leukemia , receptor , chronic lymphocytic leukemia